With the recent FDA delay, what's the deal with Sarepta Therapeutics. Seems like a sure thing but then why would the FDA delay their decision and request more data.
A good look at their clinical trail is in the WSJ this week. Where's the drug FDA?
The Food and Drug Administration is sitting on a therapy for Duchenne muscular dystrophy, and the agency may have days to waste but the boys don’t. Bureaucratic malpractice on a safe and effective treatment is corroding the agency’s scientific credibility and the public’s trust.
FDA in May delayed a decision on eteplirsen by Boston-based Sarepta Therapeutics. There is no treatment for Duchenne, a fatal disease that claims a boy’s ability to walk before organ failure in his 20s. Eteplirsen jumps over genetic code to produce a missing protein known as dystrophin.
Read more at WSJ(FYI, if you google the link title you can get around their purchase options sometimes)
A look at their stock profile: $SRPT
I have enjoyed CNBC Meg Terrill's Look at Biopharma lately as well with the upcoming elections and terrible year that Biotech has been having.
Check out more videos of Meg here. http://www.cnbc.com/meg-tirrell/
8/27/15
Biopharma Investor Further Development - Stock Trading
So it's been a minute. The principles of the Bio Pharmaceuticals of Stock investments still runs true today. I plan on continuing with the Biopharma process and provide more Data Analytical approach with Financial Data in Biotech and Pharmaceuticals. I went back to school for computer programming and data analysis and now work for a healthcare company in finance. Can't wait to provide better data analysis and web development on this website. And thankfully have enough time to work on it now.
 |
| Singapore Investing |
 |
| Protein and DNA technologies |
7/26/13
4 Best Biopharma Stock Trades 2013
Below are some of the best trades in the Biopharma Stock Sector since January 2013. I have gathered my research from a pretty good stock investment forum, 4-Trader. It's all free. I would never ask you to pay for anything on my site. No catches, no gimmicks.
If you want to search for other Sectors or other Countries, you can check them out here:
If you want to search for other Sectors or other Countries, you can check them out here:
4-Trader.com Stock Sector Research
4-Trader.com Healthcare Sector: Biotech and Pharmaceutical
These are highly potential breakout stocks that I have researched and just posting their results and how to learn more about these Top Stocks in the Healthcare Sector. More Specifically Biotech and Pharmaceutical Stocks that I predict will be doing very well in the next year with the stock market doing well and the Obamacare being implemented in 2014. There were a lot to choose from so I pick the best ones that I thought had potential for further gains.Make Money Off Obamacare
As bad as Obamacare is for business, I think it will improve the Healthcare Sector in the upcoming year and these are all good stocks that I would recommend. But you can perform your own due diligence yourself, this are the ones that stuck out to me.Top 4 Biopharma Trades
These are the all the best trades since January, most are above 50% in stock share growth. Most have higher potentials for further earnings. These are my own personal 4 picks that I thought were the best of the bunch.Santarus Inc. (SNTS)
6/7/13
Antares Pharma: $ATRS A Risky Buy
Antares Pharmaceuticals is a Hot Biopharma Investment Right Now
So let's start off with Antares Pharma. Most of my previous stocks that I have written about have done very well in the past few years so I'll continue with that trend with this stock: ATRS.
ATRS FDA Approval PDUFA Date is Oct. 14th
Antares PharmaHere's a few web links to help you out on Antares and what they are all about.
- From MarketWatch: ATRS Antares Pharma
- From Yahoo Finance: Big News with Antares Pharma Welcomes Marvin Samson to Board of Directors, from Global Manufacturing Leader, TEVA
- From Morningstar, their analysis of Antares Stock ATRS
- From Seeking Alpha: 4 Top Small Cap Biotech Acquisition Targets: Trius, Antares, Acadia, AcelRx Pharmaceuticals
- From Investor's Hub: ATRS
This is what that blogger from Seeking Alpha, Scott Matusow has to say about Antares. I agree with a commenter that a buyout would be a couple of years down the road.
Antares Pharma (ATRS)
4/16/12
Biopharma Investor
We are working on creating a new full feature design for BioPharma Investor here soon. Hopefully a better website and more updated content. Thanks for your patience while I get this up and running. Web Design and Database Programming doesn't happen overnight.
Subscribe to:
Posts (Atom)